Cosmos Health says it sees no business reason for recent share price decline

Cosmos Health Inc

COSM

0.00

Cosmos Health flagged no known business reason for the recent share price decline in a balance sheet update.
Q1 2026 total liabilities fell $4.5 million, down 9.6% quarter-on-quarter; stockholders’ equity rose $1.4 million, up 7.6%.
R&D unit in discussions with the European Investment Bank for up to EUR 25 million under its Venture Debt Program.
4,874,126 Series B Warrants expired unexercised, removing about 38% of warrant overhang with no shareholder dilution.
Wholly owned facilities valued at about $15 million; guidance projects stockholders’ equity of $92.3 million by 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606020800OMX_____CNEWS_EN_GNW9730435_en) on June 02, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.